Drugs / GR1801
last change Jan 2025 re-read 9 days ago

GR1801

Monoclonal antibody

Developed for
rabies
Investigated by
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Filed China (NMPA) — rabies —

“2025年1月,该产品用于成人疑似狂犬病病毒暴露后的被动免疫适应症的新药上市申请(NDA)获受理,正式申报上市。” genrixbio.com ↗

Trials 1

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05846568 Oct 2022 → Sep 2023 rabies Genrix (Shanghai) Biopharmaceutical Co., Ltd. Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2025-01-14 Genrix (Shanghai) Biopharmaceutical Co., Ltd. 智翔金泰狂犬病被动免疫双特异性抗体——斯乐韦米单抗注射液(GR1801)新药上市申请获得受理 genrixbio.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GR1801 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05846568 ↗
Modality Monoclonal antibody “GR1801 injections are a bispecific monoclonal antibody that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.” NCT05846568 ↗
Route Intramuscular “GR1801 injections are administered by wound infiltration injection or by intramuscular injection.” NCT05846568 ↗
Route Other “GR1801 injections are administered by wound infiltration injection or by intramuscular injection.” NCT05846568 ↗